OverviewSuggest Edit

Karo Pharma is a healthcare company, which develops and markets products for pharmacies and the health care sectors. The Company's development projects are focused on nuclear receptors as target proteins for the development of pharmaceuticals. Its products include medical compression socks, nutritional products, ergonomic products for people with disabilities, and medicine storage products. The Company also offers medicines for the treatment of sore throats, vaginal dryness, pains, etc. Its products under development include nuclear receptor RORgamma based products for the treatment of autoimmune diseases, compounds to treat multiple sclerosis and cancer, and a common cold spray.

HQStockholm, SE

Latest Updates

Employees (est.) (Feb 2021)193
Share Price (Apr 2021)KR51.2
Cybersecurity ratingBMore

Key People/Management at Karo Pharma

Christoffer Lorenzen

Christoffer Lorenzen

Chief Executive Officer
Jon Johnsson

Jon Johnsson

Chief Financial Officer
Carl Lindgren

Carl Lindgren

Vice President Business Development
Jonathan Kimber

Jonathan Kimber

VP Operations
Sofia Pedersen

Sofia Pedersen

VP Scientific Affairs
Magnus Nylén

Magnus Nylén

Chief Commercial Officer
Show more

Karo Pharma Office Locations

Karo Pharma has an office in Stockholm
Stockholm, SE (HQ)
Klara Norra kyrkogata 33
Show all (2)

Karo Pharma Financials and Metrics

Karo Pharma Revenue

Market capitalization (1-Apr-2021)


Closing stock price (1-Apr-2021)

Karo Pharma's current market capitalization is kr11.4 b.
Show all financial metrics

Karo Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Karo Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Karo Pharma Online and Social Media Presence

Embed Graph

Karo Pharma News and Updates

Karo Pharma divests Hydrokortison Trimb to Evolan Pharma

As previously communicated, Karo Pharma Aktiebolag (“Karo Pharma”) voluntarily and within a certain time undertook to divest Hydrokortison Trimb and all intellectual property rights and assets relating thereto, including necessary licenses and permits as well as existing stock, to an external buyer …

Karo Pharma buys Swedish consumer healthcare firm Trimb

Karo Pharma AB has acquired Trimb, a Swedish consumer healthcare company, for about $366 million. The deal is expected to close before the end of the year. Trimb was backed by Avista Capital Partners.

Avista Capital Partners To Sell Trimb To Karo Pharma

NEW YORK and STOCKHOLM, June 25, 2019 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused on growth-oriented healthcare businesses, today announced that Karo Pharma AB (publ) (the "Company" or "Karo Pharma"), a specialty pharma company, has acquired...

Karo Pharma publishes the 2018 annual report

Today, on 9 April 2019, Karo Pharma is publishing its annual report for 2018 on the company’s website, www.karopharma.com (http://%20www.karopharma.com).read more

Karo Pharma Blogs

Karo Pharma completes the acquisition of the brand portfolio from Teva Pharmaceuticals

Karo Pharma Aktiebolag (“Karo”) today announces that the acquisition of the European OTC brand portfolio from Teva Pharmaceuticals (Teva) for 84 MEUR, which was signed and announced on 3 February 2021, has been completed. The transaction transfers ownership of the brand portfolio, comprised of Flux …

Karo Pharma publishes the 2020 annual report

Today, on 30 March 2021, Karo Pharma is publishing its annual report for 2020 on the company’s website, www.karopharma.com. For further information, please contact: Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish versio…

Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals

Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva Pharmaceuticals (Teva) for a total consideration of EUR 84m. Inlägget Karo Pharma acquires European OTC brand portfolio from T…

Karo Pharma AB divests its Hospital Supply business, Swereco AB, to J2L Holding AB

As previously announced, Karo Pharma AB (“Karo Pharma”) has carried out a strategic evaluation of the Hospital Supply business unit, Swereco AB (“Swereco”), during the year, where a possible scenario involved a divestment. This process has now been concluded. Inlägget Karo Pharma AB divests its Hosp…

Karo Pharma publishes third-quarter report 2020 and resolves on sale of own shares

Q3, July – September Net sales amounted to MSEK 679.1 (443.7). This corresponds to an increase of 53% for the period. Following very strong growth in the first quarter the organic growth during the third quarter was -10% which follows the same pattern as during the second quarter of the year. The cu…

Second-quarter report 2020

Q2, April – June Net sales amounted to MSEK 688.9 (387.4). This corresponds to an increase of 78% for the period. The organic growth during the second quarter was -10%, currency impact 0% and 88% relates to the acquisition of Trimb in 2019 and the acquired product portfolios Proct® from Leo Pharma a…
Show more

Karo Pharma Frequently Asked Questions

  • When was Karo Pharma founded?

    Karo Pharma was founded in 1987.

  • Who are Karo Pharma key executives?

    Karo Pharma's key executives are Christoffer Lorenzen, Jon Johnsson and Carl Lindgren.

  • How many employees does Karo Pharma have?

    Karo Pharma has 193 employees.

  • Who are Karo Pharma competitors?

    Competitors of Karo Pharma include Enzymatica, OncoArendi Therapeutics and Luye Pharma.

  • Where is Karo Pharma headquarters?

    Karo Pharma headquarters is located at Klara Norra kyrkogata 33, Stockholm.

  • Where are Karo Pharma offices?

    Karo Pharma has an office in Stockholm.

  • How many offices does Karo Pharma have?

    Karo Pharma has 2 offices.